Clinical Trial Update – CRISPR-Engineered Dual...
Jan. 20, 2021
Chinese PLA General Hospital
Relapsed or Refractory Acute Lymphocytic Leukemia, ALL, (NCT06481735)
Sponsors:
Chinese PLA General Hospital
Sponsors:
Chinese PLA General Hospital
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
